BIODESIX BDSX 深 沪
等待开盘 08-26 09:30:00 美东时间
0.4932
+0.040
+8.78%
华盛通- 最 高0.4976
- 今 开0.455
- 成交量 112.32万股
- 最 低 0.453
- 昨 收 0.4534
- 总市值 7250.04万
- 52周最高 2.00
- 市盈率 静 --
- 换手率 0.76%
- 52周最低 0.1718
- 委 比 0.00%
- 总股本 1.47亿
- 历史最高 31.99
- 量 比 2.59
- 振 幅 9.84%
- 历史最低 0.1718
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
Biodesix, a leader in personalized diagnostics, was designated as a Thermo Fisher Scientific Center of Excellence. This collaboration advanced the validation of Thermo Fisher’s Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer, earning FDA approval. Biodesix contributed validation studies and data generation for regulatory submission. The partnership aims to enhance molecular diagnostic and NGS testing capabilities ...
08-19 13:47
Biodesix shares are trading lower after the company reported mixed Q2 financial results.
Biodesix shares are trading lower after the company reported mixed Q2 financial...
08-08 05:01
Biodesix Sees FY2025 Sales $80.000M-$85.000M vs $82.013M Est
Biodesix (NASDAQ:BDSX) sees FY2025 sales of $80.000 million-$85.000 million vs $82.013 million analyst estimate.
08-08 04:29
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
Biodesix, Inc. announced that CEO Scott Hutton and CFO Robin Cowie will participate in a fireside chat and hold 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The fireside chat will take place at 4:30 PM ET and will be webcast live on the Company's website. Biodesix provides diagnostic solutions for lung disease patients and offers development services to biopharmaceutical and research ...
08-05 10:00
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
Biodesix, Inc. will release its second-quarter 2025 financial results on August 7, followed by a conference call and webcast at 4:30 p.m. ET. Listeners can register via the provided links, with a replay available later on the company’s investor website. Biodesix offers diagnostic tests and development services to improve patient outcomes and support biopharmaceutical research. Forward-looking statements in this release involve risks and uncertain...
07-24 10:00
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Biodesix and APAPP collaborate to launch educational programs for healthcare providers on innovative diagnostic biomarkers, such as Nodify Lung® and IQLung® blood tests, to improve early detection and personalized treatment for lung cancer patients. The partnership aims to empower providers, especially in rural and resource-limited settings, to enhance patient care and outcomes.
06-10 10:17
Biodesix Has Been Granted European Patent Number EP3698144 Titled "COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER".
https://register.epo.org/application?number=EP18868355
06-07 04:08
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 72.6% to $0.47 during Wedne...
05-22 01:06
